These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 26883083)

  • 41. [Intercalated Combination of Chemotherapy and EGFR-TKIs versus Chemotherapy Alone in the First-line Treatment of Advanced Non-small Cell Lung Cancer: A Meta-analysis].
    Hong C; Mei T; Wang J
    Zhongguo Fei Ai Za Zhi; 2016 Dec; 19(12):837-846. PubMed ID: 27978869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A phase 2 study of bevacizumab in combination with carboplatin and paclitaxel in patients with non-squamous non-small-cell lung cancer harboring mutations of epidermal growth factor receptor (EGFR) after failing first-line EGFR-tyrosine kinase inhibitors (HANSHIN Oncology Group 0109).
    Hattori Y; Satouchi M; Shimada T; Urata Y; Yoneda T; Mori M; Nishimura T; Sunadome H; Kumagai T; Imamura F; Fujita S; Kaji R; Hata A; Tachihara M; Morita S; Negoro S
    Lung Cancer; 2015 Feb; 87(2):136-40. PubMed ID: 25553650
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Polymorphisms in epidermal growth factor receptor (EGFR) and AKT1 as possible predictors of clinical outcome in advanced non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors.
    Zhang X; Fan J; Li Y; Lin S; Shu P; Ni J; Qin S; Zhang Z
    Tumour Biol; 2016 Jan; 37(1):1061-9. PubMed ID: 26269114
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.
    Chen YM; Lai CH; Rau KM; Huang CH; Chang HC; Chao TY; Tseng CC; Fang WF; Chen YC; Chung YH; Wang YH; Su MC; Huang KT; Liu SF; Chen HC; Chang YC; Chang YP; Wang CC; Lin MC
    Lung Cancer; 2016 Aug; 98():99-105. PubMed ID: 27393514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers reduced dementia risk in patients with diabetes mellitus and hypertension.
    Kuan YC; Huang KW; Yen DJ; Hu CJ; Lin CL; Kao CH
    Int J Cardiol; 2016 Oct; 220():462-6. PubMed ID: 27390970
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Outcomes of First-Generation EGFR-TKIs Against Non-Small-Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Post Hoc Analysis of the BE-POSITIVE Study.
    Pilotto S; Rossi A; Vavalà T; Follador A; Tiseo M; Galetta D; Morabito A; Di Maio M; Martelli O; Caffo O; Piovano PL; Cortinovis D; Zilembo N; Casartelli C; Banna GL; Ardizzoia A; Barzelloni ML; Bearz A; Genestreti G; Mucciarini C; Filipazzi V; Menis J; Rizzo E; Barbieri F; Rijavec E; Cecere F; Spitaleri G; Bria E; Novello S
    Clin Lung Cancer; 2018 Jan; 19(1):93-104. PubMed ID: 28645631
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Renin-angiotensin system blockers and residual kidney function loss in patients initiating peritoneal dialysis: an observational cohort study.
    Shen JI; Saxena AB; Vangala S; Dhaliwal SK; Winkelmayer WC
    BMC Nephrol; 2017 Jun; 18(1):196. PubMed ID: 28623899
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Blood pressure, antihypertensive treatment, and graft survival in kidney transplant patients.
    Hillebrand U; Suwelack BM; Loley K; Lang D; Reuter S; Amler S; Pavenstädt H; Hausberg M; Büssemaker E
    Transpl Int; 2009 Nov; 22(11):1073-80. PubMed ID: 19624495
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of renin-angiotensin system inhibitors on long-term survival in patients treated with beta blockers and antiplatelet agents after acute myocardial infarction (from the MONICA/KORA Myocardial Infarction Registry).
    Amann U; Kirchberger I; Heier M; Zirngibl A; von Scheidt W; Kuch B; Peters A; Meisinger C
    Am J Cardiol; 2014 Aug; 114(3):329-35. PubMed ID: 24927969
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study.
    Seto T; Kato T; Nishio M; Goto K; Atagi S; Hosomi Y; Yamamoto N; Hida T; Maemondo M; Nakagawa K; Nagase S; Okamoto I; Yamanaka T; Tajima K; Harada R; Fukuoka M; Yamamoto N
    Lancet Oncol; 2014 Oct; 15(11):1236-44. PubMed ID: 25175099
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prolonged survival of patients with EGFR-mutated non-small cell lung cancer with solitary brain metastases treated with surgical resection of brain and lung lesions followed by EGFR TKIs.
    Gui Q; Liu J; Li D; Xu C
    World J Surg Oncol; 2017 Oct; 15(1):184. PubMed ID: 29037198
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Increased tumor response to neoadjuvant therapy among rectal cancer patients taking angiotensin-converting enzyme inhibitors or angiotensin receptor blockers.
    Morris ZS; Saha S; Magnuson WJ; Morris BA; Borkenhagen JF; Ching A; Hirose G; McMurry V; Francis DM; Harari PM; Chappell R; Tsuji S; Ritter MA
    Cancer; 2016 Aug; 122(16):2487-95. PubMed ID: 27203227
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in patients with abdominal aortic aneurysms: nation-wide cohort study.
    Kristensen KE; Torp-Pedersen C; Gislason GH; Egfjord M; Rasmussen HB; Hansen PR
    Arterioscler Thromb Vasc Biol; 2015 Mar; 35(3):733-40. PubMed ID: 25633315
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Angiotensin receptor blocker vs ACE inhibitor effects on HDL functionality in patients on maintenance hemodialysis.
    Kaseda R; Tsuchida Y; Gamboa JL; Zhong J; Zhang L; Yang H; Dikalova A; Bian A; Davies S; Fogo AF; Linton MF; Brown NJ; Ikizler TA; Kon V
    Nutr Metab Cardiovasc Dis; 2018 Jun; 28(6):582-591. PubMed ID: 29691148
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of melanoma antigen gene A3 expression in drug resistance of epidermal growth factor receptor-tyrosine kinase inhibitors in advanced nonsmall cell lung cancer treatment.
    Jin J; Liu BZ; Wu ZM
    J Cancer Res Ther; 2015 Nov; 11 Suppl():C271-4. PubMed ID: 26612451
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Post-Progression Survival after EGFR-TKI for Advanced Non-Small Cell Lung Cancer Harboring EGFR Mutations.
    Kogure Y; Saka H; Oki M; Saito TI; Ahmed SN; Kitagawa C; Imaizumi K
    PLoS One; 2015; 10(8):e0135393. PubMed ID: 26262682
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Interaction of Treatment and Biomarker in Advanced Non-small Cell Lung Cancer.
    Fu P; Pennell NA; Sharma N; Yi Q; Dowlati A
    Rev Recent Clin Trials; 2017; 12(1):51-58. PubMed ID: 27633965
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Is There a Survival Benefit of First-Line Epidermal Growth Factor Receptor Tyrosine-Kinase Inhibitor Monotherapy Versus Chemotherapy in Patients with Advanced Non-Small-Cell Lung Cancer?: A Meta-Analysis.
    Guetz GD; Landre T; Uzzan B; Chouahnia K; Nicolas P; Morere JF
    Target Oncol; 2016 Feb; 11(1):41-7. PubMed ID: 26092590
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Harboring Wild-type Epidermal Growth Factor Receptor: A Meta-analysis of 25 RCTs.
    Sheng Z; Zhang Y
    Am J Clin Oncol; 2017 Aug; 40(4):362-369. PubMed ID: 25647830
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Initiation, Continuation, or Withdrawal of Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers and Outcomes in Patients Hospitalized With Heart Failure With Reduced Ejection Fraction.
    Gilstrap LG; Fonarow GC; Desai AS; Liang L; Matsouaka R; DeVore AD; Smith EE; Heidenreich P; Hernandez AF; Yancy CW; Bhatt DL
    J Am Heart Assoc; 2017 Feb; 6(2):. PubMed ID: 28189999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.